Ellodi Pharmaceuticals Welcomes Debra Silberg MD, PhD, FACG to its Board of Directors
Ellodi Pharmaceuticals, a gastroenterology-focused specialty pharmaceutical company dedicated to the continued development of APT-1011, a novel, investigational oral therapy for the treatment of Eosinophilic Esophagitis (EoE), announced that Debra Silberg, MD, PhD, FACG has joined the company’s board of directors. Dr. Silberg will also serve as a Scientific Advisor.
Dr. Silberg is an accomplished life sciences executive with deep experience across all stages of drug development. She serves as a Scientific Advisor to multiple pharmaceutical companies and has held clinical leadership roles at AstraZeneca, Shire, and most recently, Takeda, where she served as the company’s Global Vice President of Clinical Development and Clinical Science Head for Gastroenterology. In this role, she was responsible for the Gastrointestinal (GI) program team, which included approximately 30 physicians and clinical scientists across the US, Europe, China, and Japan who were focused on several GI diseases, including EoE. Additionally, Dr. Silberg oversaw the clinical aspects and led discussions with regulatory authorities (FDA and EMA) to facilitate the advancement of numerous GI development programs.
“This is an exciting time to be joining the Ellodi board,” said Debra Silberg. “I look forward to working with my fellow directors to support the Ellodi management team as it continues to progress APT-1011 through development and towards NDA submission and FDA approval for the treatment of EoE.”
“Deb’s deep experience in the pharmaceutical industry coupled with her extensive clinical acumen is an invaluable addition to our team. Her vision, engagement, and leadership have shaped the future of many organizations and I expect she will have the same impact on the development of APT-1011,” said Troy Hamilton, CEO of Ellodi Pharmaceuticals. “As we continue to build Ellodi, we see an opportunity for the company to emerge as a leader in EoE and in the gastroenterology market.”
“We are pleased to welcome Dr. Silberg to Ellodi’s board as we continue to advance the development APT-1011,” said John R. Schilling, MD, Partner at TPG Capital and Chairman of Ellodi Pharmaceuticals. “Dr. Silberg has an established track record of successful GI drug development and FDA approvals, and her partnership, expertise, and guidance will be hugely valuable to our management team.”
Ellodi Pharmaceuticals is now supported by a board of seven executives who have spent their careers in the healthcare sector and bring significant clinical, regulatory, operational, and managerial expertise to the company. The board will continue to provide guidance on the ongoing strategic direction of Ellodi Pharmaceuticals as it works towards the completion and commercialization of the APT-1011 development program.
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more